Lipoic acid is a selective, small molecule large-conductance Ca(2+)-activated K(+) channel (BKCa, KCa1.1, MaxiK) positive modulator with EC50 of 11 uM. Lipoic acid shows a favorable selectivity profile on Nav, Cav, SK, and IK channels. Lipoic acid causes distinct activation from a concentration of 0.3 and 10 µM Lipoic acid left-shifted the voltage activation curve by 60 mV. Lipoic acid reduces spontaneous phasic contractions in guinea pig urinary bladder strips at 1 uM, while having only a modest effect on contractions evoked by electrical field stimulation (EFS) and no effect on high K+-induced contractions.

A small molecule inhibitor of NEMO (IKKγ)-ubiquitin binding with EC50 of 9.3 uM, directly binds to NEMO with Kd of 2.14 uM.

A small molecule that inhibits NFATc1 and NF-κB activity, inhibits RANKL-induced osteoclastogenesis in vivo.

ABD328 (ABD-328) is an orally active, small molecule inhibitor of RANKL and TNF signalling that inhibits inflammation in vivo.

AM-0216 (Amgen16) is a highly potent inhibitor of NF-κB inducing Kinase (NIK) with Ki of 2 nM, selectively decrease viability of MMCLs in which NFkB activity is NIK-dependent.

AM-0561 (AM0561) is a highly potent inhibitor of NF-κB inducing Kinase (NIK) with Ki of 0.3 nM..

Amgen16 is a highly potent inhibitor of NF-κB inducing Kinase (NIK), example 294 in patent WO 2009158011 A1..

AZD 3264 is an IkB-kinase IKK2 Inhibitor, IKK2 has been identified as one of the novel pathways to treat inflammatory conditions such as asthma, chronic pulmonary obstructive disorder (COPD) and rheumatoid arthritis.

BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM. Also inhibiting components of the ubiquitin system.

BAY 11-7085 is an irreversible inhibitor of TNFα-induced IκBα phosphorylation with an IC50 value of 10 μM.

BI605906 is a potent, specific IKKβ inhibitor with IC50 of 380 nM (0.1 mM ATP), does not suppress signaling downstream of mTOR or activate AMPK.

Didox is a simple, synthetic antioxidant that has been found to reduce the levels of oxidative injury markers.

Edasalonexent (CAT-1004) is a bifunctional, orally administered small molecule that covalently links 2 compounds known to inhibit NF‐κB, salicylic acid and docosahexaenoic acid (DHA).

Iguratimod is one of a series of 4H-1-benzopyran-4-ones which has potent anti-inflammatory, analgesic and antipyretic activity.

IKK 16 is a selective IκB kinase (IKK) inhibitor for IKK-2, IKK complex and IKK-1 with IC50 of 40 nM, 70 nM and 200 nM, respectively.

IKK 16 is a selective IκB kinase (IKK) inhibitor for IKK-2, IKK complex and IKK-1 with IC50 of 40 nM, 70 nM and 200 nM, respectively.

IKK-2 inhibitor VIII is a potent and selective IKK-2 inhibitor with IC50 of 8.5 nM.

IKKε-IN-1 is a potent IKKε inhibitor; inhibit the in-situ ΙKΚ ε-mediated phosphorylation of IRF3 with an IC50 value of less than about 100 nM.

IMD-0354 is a synthetic selective NF-kB inhibitor.

IT 901 is a c-Rel inhibitor (IC50 = 3 μM). Inhibits IL-2 expression in activated T-cells in vitro.

JSH-23 is an inhibitor of NF-κB transcriptional activity with IC50 of 7.1 μM.

LY2409881 is a novel inhibitor of IκB kinase β (IKK2).